J. Traynor

发表

Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.

S. Breeden, M. Aceto, C. Neilan, 2004, European journal of pharmacology.

Structural insights into μ-opioid receptor activation

Stephen M. Husbands, A. J. Venkatakrishnan, Ron O. Dror, 2015, Nature.

Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.

J. Woods, J. Traynor, I. McFadyen, 2001, The Journal of pharmacology and experimental therapeutics.

A Spatial Focusing Model for G Protein Signals

Peter J Woolf, Jennifer J Linderman, Richard R Neubig, 2003, The Journal of Biological Chemistry.

pKa and Volume of residue one influence δ/μ opioid binding: QSAR analysis of tyrosine replacement in a nonselective deltorphin analogue

D. Rodgers, J. Traynor, S. E. Schullery, 2003 .

Nitrile analogs of meperidine as high affinity and selective sigma-1 receptor ligands.

A. Coop, J. Traynor, R. Matsumoto, 2008, European journal of medicinal chemistry.

5-HT1A receptor-mediated phosphorylation of extracellular signal-regulated kinases (ERK1/2) is modulated by regulator of G protein signaling protein 19.

Qin Wang, J. Traynor, H. Umemori, 2014, Cellular signalling.

Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.

P. Szekeres, J. Traynor, Philip G. Szekeres, 1997, The Journal of pharmacology and experimental therapeutics.

Comparison of the Relative Efficacy and Potency of μ-Opioid Agonists to Activate Gαi/o Proteins Containing a Pertussis Toxin-Insensitive Mutation

J. Traynor, M. Clark, Cheryse A. Furman, 2006, Journal of Pharmacology and Experimental Therapeutics.

Dynamic Coupling and Allosteric Networks in the α Subunit of Heterotrimeric G Proteins*

Xin-Qiu Yao, B. Grant, J. Traynor, 2015, The Journal of Biological Chemistry.

Endogenous Regulators of G Protein Signaling Differentially Modulate Full and Partial μ-Opioid Agonists at Adenylyl Cyclase as Predicted by a Collision Coupling Model

J. Linderman, J. Traynor, M. Clark, 2008, Molecular Pharmacology.

Mediation of adenylyl cyclase sensitization by PTX‐insensitive GαoA, Gαi1, Gαi2 or Gαi3

J. Traynor, M. Clark, 2006 .

Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.

Kathryn E. Livingston, A. Christopoulos, M. Banks, 2015, Journal of medicinal chemistry.

Selectively Promiscuous Opioid Ligands: Discovery of High Affinity/Low Efficacy Opioid Ligands with Substantial Nociceptin Opioid Peptide Receptor Affinity

I. Pogozheva, Vinod Kumar, H. Mosberg, 2014, Journal of medicinal chemistry.

GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys.

J. Vivian, M. Ko, J. Woods, 2001, The Journal of pharmacology and experimental therapeutics.

GR89,696: A Potent κ-Opioid Agonist with Subtype Selectivity in Rhesus Monkeys

J. Vivian, M. Ko, J. Woods, 2001 .

Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys.

M. Ko, J. Woods, J. Traynor, 2003, The Journal of pharmacology and experimental therapeutics.

The Intriguing Effects of Substituents in the N-Phenethyl Moiety of Norhydromorphone: A Bifunctional Opioid from a Set of “Tail Wags Dog” Experiments

Sarah L. Withey, S. Hassan, K. Rice, 2020, Molecules.

Synthesis and biological evaluation of 14-alkoxymorphinans. 14.1 14-ethoxy-5-methyl substituted indolomorphinans with δ opioid receptor selectivity

J. Traynor, A. Borsodi, H. Schmidhammer, 1997 .

The selectivity of the opioid antagonist, naltrindole, for δ‐opioid receptors

A. Lawrence, J. Traynor, H. Rogers, 1990 .

Differential effects of opioid peptides on myocardial ischemic tolerance.

S. Bolling, J. Traynor, M. Romano, 2004, The Journal of surgical research.

The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors

R. Neubig, Qin Wang, E. Jutkiewicz, 2016, Psychopharmacology.

Differential Modulation of μ- and δ-Opioid Receptor Agonists by Endogenous RGS4 Protein in SH-SY5Y Cells*

Qin Wang, L. Liu-Chen, J. Traynor, 2009, The Journal of Biological Chemistry.

RGS inhibition at Gαi2 selectively potentiates 5-HT1A–mediated antidepressant effects

Steven M. Graves, R. Neubig, E. Jutkiewicz, 2010, Proceedings of the National Academy of Sciences.

Opioid-induced Down-Regulation of RGS4

Qin Wang, J. Traynor, 2011, The Journal of Biological Chemistry.

Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats.

E. Jutkiewicz, K. Rice, J. Woods, 2002, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.

S. Breeden, M. Aceto, C. Neilan, 2005, European journal of pharmacology.

14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.

S. Husbands, J. Lewis, J. Traynor, 2003, Journal of medicinal chemistry.

Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.

S. Srivastava, M. Aceto, S. Husbands, 2004, Journal of medicinal chemistry.

Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

I. Pogozheva, H. Mosberg, J. Traynor, 2011, ACS chemical biology.

Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the κ‐opioid receptor

I. Pogozheva, H. Mosberg, J. Traynor, 2005 .

Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.

I. Pogozheva, H. Mosberg, J. Traynor, 2005, The journal of peptide research : official journal of the American Peptide Society.

Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.

H. Mosberg, J. Traynor, I. McFadyen, 2000, The Journal of pharmacology and experimental therapeutics.

Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation.

H. Mosberg, J. Traynor, I. McFadyen, 2000, The journal of peptide research : official journal of the American Peptide Society.

Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models.

H. Mosberg, J. Traynor, I. McFadyen, 1998, Bioorganic & medicinal chemistry letters.

Opioid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

E. J. Simon, H. Ueda, M. Bruchas, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

RGS-insensitive mice define roles of mu opioid receptor (MOR)-Gαo and Gαi subunit coupling in inhibition of presynaptic GABA release.

J. Traynor, Ming-hua Li, S. Ingram, 2021, Molecular pharmacology.

Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management

J. Traynor, R. Kandasamy, Nicolas B. Senese, 2020, Frontiers in Molecular Neuroscience.

Differential Control of Opioid Antinociception to Thermal Stimuli in a Knock-In Mouse Expressing Regulator of G-Protein Signaling-Insensitive Gαo Protein

R. Neubig, J. Traynor, Ming-hua Li, 2013, The Journal of Neuroscience.

Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80

R. Neubig, E. Jutkiewicz, K. Rice, 2017, British journal of pharmacology.

The [35S]GTPγS binding assay: approaches and applications in pharmacology

J. Traynor, C. Harrison, J. Traynor, 2003 .

The [35S]GTPgammaS binding assay: approaches and applications in pharmacology.

J. Traynor, C. Harrison, 2003, Life sciences.

Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.

E. Jutkiewicz, H. Mosberg, J. Traynor, 2015, ACS chemical neuroscience.

HL-1 Myocytes Exhibit PKC and KATP Channel-Dependent

S. Bolling, W. Claycomb, J. Traynor, 2003 .

HL-1 myocytes exhibit PKC and K(ATP) channel-dependent delta opioid preconditioning.

S. Bolling, W. Claycomb, J. Traynor, 2003, The Journal of surgical research.

Alkylation with β‐funaltrexamine suggests differences between μ‐opioid receptor systems in guinea‐pig brain and myenteric‐plexus

J. Traynor, J. Traynor, T. G. Franklin, 1991 .

Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands.

J. Traynor, A. Alt, Keith M. Olson, 2022, ACS pharmacology & translational science.

Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

I. Pogozheva, H. Mosberg, J. Traynor, 2009, Journal of medicinal chemistry.

Dynorphin A(1-8): stability and implications for in vitro opioid activity.

J. Traynor, K. M. Bell, K. Bell, 1998, Canadian journal of physiology and pharmacology.

Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands

I. Pogozheva, E. Jutkiewicz, H. Mosberg, 2016, Journal of medicinal chemistry.

Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy Mu-Opioid Receptor (MOR)/Delta-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.

I. Pogozheva, E. Jutkiewicz, H. Mosberg, 2020, Journal of medicinal chemistry.

C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors

Vinod Kumar, S. Husbands, J. Lewis, 2015, Journal of medicinal chemistry.

Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity

Mark P Thomas, M. Aceto, S. Husbands, 2013, Journal of medicinal chemistry.

Modulation of Opioid Receptor Ligand Affinity and Efficacy Using Active and Inactive State Receptor Models

I. Pogozheva, H. Mosberg, J. Traynor, 2012, Chemical biology & drug design.

Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase.

Paul M. Jenkins, J. Martens, J. Traynor, 2009, The Journal of biological chemistry.

Opioid receptor interacting proteins and the control of opioid signaling.

J. Traynor, J. Lamberts, 2014, Current pharmaceutical design.

Receptor binding kinetics and cellular responses of six N-formyl peptide agonists in human neutrophils.

Tamara L. Kinzer-Ursem, J. Linderman, A. Waller, 2004, Biochemistry.

Synthesis and In Vivo Brain Distribution of Carbon-11 Labeled δ Opioid Receptor Agonists 1

D. Jewett, J. Woods, J. Traynor, 2011 .

Increased Agonist Affinity at the μ-Opioid Receptor Induced by Prolonged Agonist Exposure

John T. Williams, K. Rice, J. Traynor, 2013, The Journal of Neuroscience.

The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice

E. Jutkiewicz, S. Husbands, J. Traynor, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show In Vitro Kappa and Mu Opioid Receptor Agonism.

I. Pogozheva, H. Mosberg, J. Traynor, 2019, ACS chemical neuroscience.

Structure–Activity Relationships of 7-Substituted Dimethyltyrosine-Tetrahydroisoquinoline Opioid Peptidomimetics

H. Mosberg, J. Traynor, Jessica P. Anand, 2019, Molecules.

Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats

E. Jutkiewicz, K. Rice, J. Woods, 2005, Psychopharmacology.

Stimulation of polymorphonuclear leucocyte phospholipase A2 activity by chloroquine and mepacrine

J. Traynor, K. Authi, J. Traynor, 1982, The Journal of pharmacy and pharmacology.

Phospholipase A2 activity of lysosomal origin secreted by polymorphonuclear leucocytes during phagocytosis or on treatment with calcium.

J. Traynor, K. Authi, 1981, Biochimica et biophysica acta.

Effects of antimalarial drugs on phospholipase A2

J. Traynor, K. Authi, 1979 .

Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible μ Opioid Receptor Antagonist Effects

Mark P Thomas, M. Aceto, L. Harris, 2012, Journal of medicinal chemistry.

Comparison of Receptor Mechanisms and Efficacy Requirements for δ-Agonist-Induced Convulsive Activity and Antinociception in Mice

J. Pintar, K. Rice, J. Woods, 2002, Journal of Pharmacology and Experimental Therapeutics.

OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects

S. Husbands, J. Traynor, C. France, 2022, Behavioural pharmacology.

Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.

Anthony F. Nastase, E. Jutkiewicz, H. Mosberg, 2019, Journal of medicinal chemistry.

Inhibition of rat liver cholesterol esterase by local anaesthetics.

J. Traynor, H. Kunze, 1975, Biochimica et biophysica acta.

In vitro Pharmacology of Fentanyl Analogs at the Human Mu Opioid Receptor and Their Spectroscopic Analysis.

J. Traynor, Jessica P. Anand, Sherif H. Hassanien, 2020, Drug testing and analysis.

Thienorphine: Receptor Binding and Behavioral Effects in Rhesus Monkeys

J. Traynor, C. France, G. L. Becker, 2007, Journal of Pharmacology and Experimental Therapeutics.

Differential in Vivo Potencies of Naltrexone and 6β-Naltrexol in the Monkey

M. Ko, J. Woods, J. Traynor, 2006, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.

M. Aceto, L. Harris, A. Coop, 2003, Journal of medicinal chemistry.

14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships

Received December, M. Aceto, L. Harris, 2003 .

BU48: A Novel Buprenorphine Analog That Exhibits δ-Opioid-Mediated Convulsions but Not δ-Opioid-Mediated Antinociception in Mice

A. Coop, S. Husbands, J. Lewis, 2000 .

Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.

T. Sumpter, S. Husbands, J. Woods, 2000, Journal of Pharmacology and Experimental Therapeutics.

Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor.

H. Akil, J. Woods, J. Traynor, 1998, The Journal of pharmacology and experimental therapeutics.

Regulators of G-Protein Signaling (RGS) Proteins Promote Receptor Coupling to G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channels

J. Traynor, Ming-hua Li, C. Meurice, 2018, The Journal of Neuroscience.

THIS IS THE FINAL DRAFT POST-REFEREEING AND IS ALLOWED TO BE MADE AVAILABLE, WHERE THE HOST INSTITUTION MANDATES IT, AFTER 12 MONTHS EMBARGO

S. Husbands, J. Traynor, Daniel P. Furkert, 2015 .

Characterization of BU09059: a novel potent selective κ-receptor antagonist.

S. Husbands, J. Traynor, Daniel P. Furkert, 2014, ACS chemical neuroscience.

Inhibition of an inflammatory exudate phospholipase A2 by an endogenous inhibitor of polymorphonuclear leucocytes.

J. Traynor, K. Authi, A. Solanky, 1982, Pharmacological research communications.

μ-Opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPγS binding assays

B. Roques, R. Maldonado, J. Traynor, 1999 .

In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor

S. Husbands, J. Traynor, M. Clark, 2013, Journal of psychopharmacology.

Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.

S. Husbands, J. Traynor, J. Lewis, 2014, Bioorganic & medicinal chemistry.

Role of protein kinase C in functional selectivity for desensitization at the µ‐opioid receptor: from pharmacological curiosity to therapeutic potential

J. Traynor, S. Ingram, 2009, British journal of pharmacology.

THEMED ISSUE: GPCR COMMENTARY Role of protein kinase C in functional selectivity for desensitization at the m-opioid receptor: from pharmacological curiosity to therapeutic potential

J. Traynor, S. Ingram, 2009 .

Differential modulation of mu‐opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Gα subtype dependent

R. Neubig, J. Traynor, D. Roman, 2010, Journal of neurochemistry.

Role of gonadal hormones on mu-opioid-stimulated [35S]GTPγS binding and morphine-mediated antinociception in male and female Sprague–Dawley rats

Steven M. Graves, J. Becker, E. Jutkiewicz, 2011, Psychopharmacology.

Comparison of the Antinociceptive Response to Morphine and Morphine-Like Compounds in Male and Female Sprague-Dawley Rats

J. Traynor, E. M. Peckham, 2006, Journal of Pharmacology and Experimental Therapeutics.

Comparison of the in vitro efficacy of μ, δ, κ and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes

J. Traynor, P. Lester, 2006, Brain Research.

Comparison of the antinociceptive effect of acute morphine in female and male Sprague–Dawley rats using the long-lasting mu-antagonist methocinnamox

J. Traynor, T. Cicero, M. F. Divin, 2005, Brain Research.

Characterization of ZFOR1, a putative delta-opioid receptor from the teleost zebrafish (Danio rerio)

R. González-Sarmiento, J. Traynor, I. McFadyen, 2000, Neuroscience Letters.

Characterization of Opioid-Binding Sites in Zebrafish Brain

J. Traynor, V. González-Nuñez, A. Barrallo, 2006, Journal of Pharmacology and Experimental Therapeutics.

The steroid 17alpha-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3, 5-dien-20-one (SC17599) is a selective mu-opioid agonist: implications for the mu-opioid pharmacophore.

H. Houshyar, L. Liu-Chen, J. Woods, 2000, Molecular pharmacology.

Opiate binding in the rat spinal cord: Evidence for mu and delta sites

J. Traynor, M. J. Rance, 1984, Neuropeptides.

Isolation and Chemical Modification of Clerodane Diterpenoids from Salvia Species as Potential Agonists at the κ‐Opioid Receptor

S. Husbands, J. Traynor, M. Mahon, 2007, Chemistry & biodiversity.

Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.

J. Deschamps, S. Hassan, K. Rice, 2017, Bioorganic & medicinal chemistry.

Formation of [Leu5]Enkephalin from Dynorphin A(1–8) by Rat Central Nervous Tissue In Vitro

J. Traynor, D. Dixon, 1990, Journal of neurochemistry.

Convulsant activity of a non-peptidic δ-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats

E. Jutkiewicz, K. Rice, J. Woods, 2002, Psychopharmacology.

Kappa opioid binding sites in rat spinal cord.

J. Traynor, J. Carroll, M. J. Rance, 1986, NIDA research monograph.

Multiple opiate binding sites in rat spinal cord.

J. Traynor, M. J. Rance, P. D. Kelly, 1982, Life sciences.

Opiate receptors in rat spinal cord

J. Traynor, A. C. Lane, M. J. Rance, 1980 .

Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.

H. Akil, C. Neilan, J. Woods, 1999, British journal of pharmacology.

An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional δ -Opioid Receptor

S. Bolling, W. Claycomb, C. Neilan, 2000 .

Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice

E. Jutkiewicz, K. Rice, J. Traynor, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Sodium ions increase the binding of the antagonist peptide ICI 174864 to the δ-opiate receptor

E. J. Simon, J. Traynor, J. Carroll, 1986, Neuropeptides.

Constitutive activity of the δ‐opioid receptor expressed in C6 glioma cells: identification of non‐peptide δ‐inverse agonists

H. Akil, C. Neilan, J. Woods, 1999 .

The Spinal Antinociceptive Effects of Endomorphins in Rats: Behavioral and G Protein Functional Studies

J. Woods, J. Traynor, M. Ko, 2008, Anesthesia and analgesia.

The effects of the phyllolitorin analogue [desTrp3,Leu8]phyllolitorin on scratching induced by bombesin and related peptides in rats

Mark D. Johnson, H. Mosberg, J. Woods, 1999, Brain Research.

Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

J. Woods, J. Traynor, E. Butelman, 1998, The Journal of pharmacology and experimental therapeutics.

Orphanin FQ inhibits capsaicin‐induced thermal nociception in monkeys by activation of peripheral ORL1 receptors

K. Rice, M. Ko, J. Woods, 2002, British journal of pharmacology.

Mixed Kappa/Mu Opioid Receptor Agonists: The 6 β Naltrexamines

A. Neal, L. Harris, J. Traynor, 2011 .

Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-Hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime.

J. Traynor, D. Patel, H. Schmidhammer, 1995, Journal of medicinal chemistry.

N-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties : Extending the Scope of Common Structure-Activity Relationships

M. Aceto, L. Harris, A. Coop, 2022 .

Regioselective 2-hydroxylation of 3-methoxyoestra-1,3,5(10)-trienes via chromium carbonyl complexes

B. Marples, J. Traynor, J. C. Gill, 1987 .

Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.

E. Jutkiewicz, H. Mosberg, J. Traynor, 2013, Journal of medicinal chemistry.

Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.

Anthony F. Nastase, E. Jutkiewicz, H. Mosberg, 2018, ACS chemical neuroscience.

Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.

I. Pogozheva, E. Jutkiewicz, H. Mosberg, 2015, Journal of medicinal chemistry.

Prodynorphin as a source of [Leu] enkephalin

J. Traynor, 1987 .

Conversion of dynorphin-(1-9) to [Leu5]enkephalin by the mouse vas deferens in vitro.

J. Traynor, J. Shaw, M. J. Rance, 1985, European journal of pharmacology.

Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction.

J. Traynor, D. Roman, 2011, Journal of medicinal chemistry.

Allosteric Modulator Leads Hiding in Plain Site: Developing Peptide and Peptidomimetics as GPCR Allosteric Modulators

J. Traynor, A. Alt, Keith M Olson, 2021, Frontiers in Chemistry.

Distribution of opioid binding sites in spinal cord

J. Traynor, M. S. Wood, John R. Traynor, 1987, Neuropeptides.

Properties of opiate binding in the rat spinal cord

J. Traynor, M. J. Rance, P. D. Kelly, 1982, Neuropeptides.

Pyrrolo[1,2-a][1,3,5]triazine-2,4(1H,3H)-diones. Part II. Synthesis from 3,4-disubstituted 2-aminopyrroles

J. Traynor, D. Wibberley, 1974 .

Differential binding properties of oripavines at cloned μ- and δ-opioid receptors

H. Akil, J. Woods, J. Traynor, 1999 .

Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

J. Traynor, S. Nahorski, 1995, Molecular pharmacology.

The action of various venoms on Escherichia coli.

J. Traynor, J. F. Stocker, 1986, The Journal of applied bacteriology.

Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.

J. Traynor, P. Lester, 2006, Brain research.

Epibatidine and pain.

J. Traynor, 1998, British journal of anaesthesia.

Synthesis and in vivo brain distribution of carbon-11-labeled δ-opioid receptor agonists.

Michael R Kilbourn, D. Jewett, S. Husbands, 2010, Nuclear medicine and biology.

The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum

E. Jutkiewicz, M. Gnegy, J. Traynor, 2008, Neuropharmacology.

Comparison of Peptidic and Nonpeptidic δ-Opioid Agonists on Guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) Binding in Brain Slices from Sprague-Dawley Rats

E. Jutkiewicz, K. Rice, J. Woods, 2005, Journal of Pharmacology and Experimental Therapeutics.

δ-Opioid Agonists: Differential Efficacy and Potency of SNC80, Its 3-OH (SNC86) and 3-Desoxy (SNC162) Derivatives in Sprague-Dawley Rats

E. Jutkiewicz, K. Rice, J. Woods, 2004, Journal of Pharmacology and Experimental Therapeutics.

Comparison of peptidic and nonpeptidic delta-opioid agonists on [ 35 S ] GTP γ S binding in brain slices from Sprague-Dawley rats

E. Jutkiewicz, K. Rice, J. Woods, 2004 .

Nonpeptidic δ-opioid Receptor Agonists Reduce Immobility in the Forced Swim Assay in Rats

E. Jutkiewicz, K. Rice, J. Woods, 2002, Neuropsychopharmacology.

4'-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity.

S. Srivastava, M. Aceto, S. Husbands, 2002, Journal of medicinal chemistry.

Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects

Kathryn E. Livingston, B. Roques, J. Traynor, 2021, Proceedings of the National Academy of Sciences.

δ-opioid receptor subtypes and cross-talk with μ-receptors

John R. Traynor, J. Traynor, J. Elliott, 1993 .

Pharmacological Properties of δ-Opioid Receptor–Mediated Behaviors: Agonist Efficacy and Receptor Reserve

Kathryn E. Livingston, E. Jutkiewicz, K. Rice, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Translation of structure‐activity relationships from cyclic mixed efficacy opioid peptides to linear analogues

I. Pogozheva, H. Mosberg, J. Traynor, 2014, Biopolymers.

Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance

E. Jutkiewicz, H. Mosberg, J. Traynor, 2014, Journal of medicinal chemistry.

Opioid receptors and their subtypes: Focus on peripheral isolated tissue preparations

J. Traynor, 1994, Neurochemistry International.

N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole.

K. Rice, M. Aceto, L. Harris, 2000, Bioorganic & medicinal chemistry letters.

Molecular recognition at the myo-inositol 1,4,5-trisphosphate receptor. 3-position substituted myo-inositol 1,4,5-trisphosphate analogues reveal the binding and Ca2+ release requirements for high affinity interaction with the myo-inositol 1,4,5-trisphosphate receptor.

R. Challiss, A. Kozikowski, J. Traynor, 1994, The Journal of biological chemistry.

Pyrrolo [1,2‐a] [1,3,5] triazine‐2,4(1H, 3H)‐diones. III—Fragementation under electron‐impact

J. Traynor, 1975 .

Positive allosteric modulators of the μ‐opioid receptor: a novel approach for future pain medications

J. Traynor, A. Alt, N. Burford, 2015, British journal of pharmacology.

Regulators of G protein signaling (RGS) Proteins as Drug Targets: Modulating GPCR Signal Transduction

J. Traynor, D. Roman, 2011 .

Identification of Small-Molecule Inhibitors of RGS4 Using a High-Throughput Flow Cytometry Protein Interaction Assay

R. Neubig, R. Sunahara, J. Traynor, 2007, Molecular Pharmacology.

Modulation of μ-Opioid Receptor Signaling by RGS19 in SH-SY5Y Cells

Qin Wang, J. Traynor, 2013, Molecular Pharmacology.

Modulation of m-Opioid Receptor Signaling by RGS 19 in SH-SY 5 Y Cells

Qin Wang, J. Traynor, 2013 .

Allostery at opioid receptors: modulation with small molecule ligands

Kathryn E. Livingston, J. Traynor, 2018, British journal of pharmacology.

Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.

J. Traynor, H. Kosterlitz, A. Corbett, 1987, European journal of pharmacology.

Synthesis and Biological Evaluation of 14‐Alkoxymorphinans. Part 9. 14‐O‐ethyl‐5‐methylnaltrexone, and opioid antagonist with unusual selectivity

J. Traynor, H. Schmidhammer, D. Patel, 1993 .

Effects of local anaesthetics on phospholipases.

J. Traynor, H. Kunze, N. Nahas, 1976, Biochimica et biophysica acta.

Challenges for opioid receptor nomenclature: IUPHAR Review 9

L. Devi, J. Traynor, L. Toll, 2015, British journal of pharmacology.

Regulators of G protein signaling & drugs of abuse.

R. Neubig, J. Traynor, 2005, Molecular interventions.

Antinociceptive and other behavioral effects of the steroid SC17599 are mediated by the mu-opioid receptor.

H. Houshyar, J. Woods, J. Traynor, 2000, European journal of pharmacology.

Differential Behavioral Tolerance to the δ-Opioid Agonist SNC80 ([(+)-4-[(αR)-α-[(2S,5R)-2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley Rats

E. Jutkiewicz, K. Rice, J. Woods, 2005, Journal of Pharmacology and Experimental Therapeutics.

The δ‐opioid receptor positive allosteric modulator BMS 986187 is a G‐protein‐biased allosteric agonist

Kathryn E. Livingston, Zara Y. Weinberg, J. Traynor, 2019, British journal of pharmacology.

Themed section

J. Traynor, M. Connor, M. Christie, 2015, British journal of pharmacology.

G Protein independent phosphorylation and internalization of the δ‐opioid receptor

J. Traynor, F. Bradbury, Faye A. Bradbury, 2009, Journal of neurochemistry.

Convulsive Behavior of Nonpeptide δ-Opioid Ligands:Comparison of SNC80 and BW373U86 in Mice

K. Rice, J. Woods, J. Traynor, 1998 .

Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors.

R. Neubig, Xi-Ping Huang, Qin Wang, 2015, ACS chemical neuroscience.

Characterisation of μ-opioid receptors on SH-SY5Y cells using naloxonazine and β-funaltrexamine

D. Lambert, J. Traynor, D. Smart, 1994 .

Effects of antimalarial drugs on phospholipase A2 [proceedings].

J. Traynor, K. Authi, 1979, British journal of pharmacology.

DEVELOPMENT AND IN VITRO CHARACTERIZATION OF A NOVEL BIFUNCTIONAL MU-AGONIST/DELTA-ANTAGONIST OPIOID TETRAPEPTIDE

I. Pogozheva, H. Mosberg, J. Traynor, 2011 .

Opioid research in the time of the opioid crisis

J. Traynor, J. Morón, John R. Traynor, 2023, British journal of pharmacology.

Behavioral effects of δ-opioid receptor agonists: Potential antidepressants?

E. Jutkiewicz, K. Rice, J. Woods, 2002 .

kappa-Opioid receptor effects of butorphanol in rhesus monkeys.

T. Sumpter, J. Vivian, J. Woods, 1999, The Journal of pharmacology and experimental therapeutics.

k -Opioid Receptor Effects of Butorphanol in Rhesus Monkeys 1

T. Sumpter, J. Vivian, J. Woods, 1999 .

Endogenous Regulator of G Protein Signaling Proteins Reduce μ-Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells

J. Traynor, M. Clark, 2005, Journal of Pharmacology and Experimental Therapeutics.

Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism

O. Mabrouk, R. Kennedy, E. Jutkiewicz, 2014, Neuropharmacology.

Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor

M. Banks, S. Gerritz, J. Traynor, 2013, Proceedings of the National Academy of Sciences.

In vivo effects of μ‐opioid receptor agonist/δ‐opioid receptor antagonist peptidomimetics following acute and repeated administration

Anthony F. Nastase, E. Jutkiewicz, H. Mosberg, 2018, British journal of pharmacology.

Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence

E. Jutkiewicz, J. Traynor, J. Lamberts, 2017, Psychopharmacology.

Guanidino N-Substituted and N,N-Disubstituted Derivatives of the κ-Opioid Antagonist GNTI

S. Husbands, J. Lewis, J. Traynor, 2003 .

Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.

S. Husbands, J. Lewis, J. Traynor, 2006, Journal of medicinal chemistry.

μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology.

J. Traynor, 2012, Drug and alcohol dependence.

The μ-opioid receptor

J. Traynor, 1996 .

Delta Opioid Receptors and G Proteins

J. Traynor, M. Clark, 2003 .

RESEARCH PAPER Neutral antagonist activity of naltrexone and 6b-naltrexol in naïve and opioid-dependent C6 cells expressing a m-opioid receptor

F. Carroll, J. Traynor, F. Bradbury, 2009 .

CHALLENGES FOR OPIOID RECEPTOR NOMENCLATURE

L. Devi, J. Traynor, L. Toll, 2016 .

Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH‐SY5Y cells

J. Woods, J. Traynor, A. Alt, 2002, British journal of pharmacology.

Endogenous Regulator of G Protein Signaling Proteins Suppress Gαo-Dependent, μ-Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization

R. Neubig, J. Traynor, M. Clark, 2004, Journal of Pharmacology and Experimental Therapeutics.

Endogenous Regulator of G Protein Signaling Proteins Suppress G (cid:1) o-Dependent, (cid:2) -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization

R. Neubig, J. Traynor, M. Clark, 2004 .

Constitutively active μ-opioid receptors.

J. Traynor, M. Connor, 2010, Methods in enzymology.

Activation of G protein by opioid receptors: role of receptor number and G-protein concentration.

J. Woods, J. Traynor, A. Alt, 2000, European journal of pharmacology.

Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor

Kathryn E. Livingston, R. Sunahara, A. Manglik, 2018, eLife.

Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.

J. Traynor, M. F. Divin, M. C. Holden Ko, 2008, European journal of pharmacology.

Constitutive activity of the d -opioid receptor expressed in C6 glioma cells: identiﬁcation of non-peptide d -inverse agonists

H. Akil, C. Neilan, J. Woods, 1999 .

Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.

H. Akil, J. Woods, J. Traynor, 1999, European journal of pharmacology.

The Role of G-proteins and G-protein Regulating Proteins in Depressive Disorders

M. Rasenick, J. Traynor, Nicolas B. Senese, 2018, Front. Pharmacol..

N-(trifluoromethyl)benzyl substituted N-normetazocines and N-norketobemidones.

M. Aceto, L. Harris, A. Coop, 2003, Bioorganic & medicinal chemistry.

[35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2, hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and norepinephrine.

M. Lehofer, P. Liebmann, J. Traynor, 2006, European journal of pharmacology.

The use of [3H]-[D-Pen2,D-Pen5]enkephalin as a highly selective ligand for the delta-binding site.

J. Traynor, H. Kosterlitz, S. Paterson, 1985, British journal of pharmacology.

The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: Benzomorphans.

M. Aceto, L. Harris, A. Coop, 2008, Bioorganic & medicinal chemistry.

Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.

M. Aceto, L. Harris, J. Woods, 2000, Journal of medicinal chemistry.

Synthesis, in vitro, and in vivo activity of N-p-substituted-benzyl- (- )- and (+)-N-normetazocines, (-)- and (+)-N-normorphinans, N- norketobemidones, and (-)-N-nor-4,5-epoxymorphinans

M. Aceto, L. Harris, A. Coop, 1998 .

Mu-Opioid Receptor Coupling to Gαo Plays an Important Role in Opioid Antinociception

E. Jutkiewicz, J. Traynor, R. Mortensen, 2011, Neuropsychopharmacology.

Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs.

A. Coop, J. Traynor, H. Hassan, 2008, Journal of medicinal chemistry.

Effects of narcotic analgesics on lipase activity in vitro.

J. Traynor, P. D. Kelly, 1982, Pharmacological research communications.

Effects of local anaesthetics on the lipase of Rhizopus arrhizus.

J. Traynor, H. Kunze, Hans Kunze, 1976, Biochimica et biophysica acta.

Conformational studies and stabilities of small dynorphin peptides

J. Traynor, D. Patel, K. Bell, 1994, Regulatory Peptides.

Conversion of dynorphin A(1–8) to [Leu5]-enkephalin in rat central nervous tissue during development

J. Traynor, D. Dixon, 1993, Neuropeptides.

Role of hippocampal 5-HT1A receptors in the antidepressant-like phenotype of mice expressing RGS-insensitive Gαi2 protein

R. Neubig, C. Ferrario, E. Jutkiewicz, 2018, Neuropharmacology.

Crystal structure of active mu-opioid receptor bound to the agonist BU72

Kathryn E. Livingston, Evan N. Feinberg, R. Dror, 2015 .

Endogenous RGS Protein Action Modulates μ-Opioid Signaling through Gαo

R. Neubig, J. Traynor, H. Zhong, 2003, The Journal of Biological Chemistry.

Regulator of G protein–signaling proteins and addictive drugs

J. Traynor, 2010, Annals of the New York Academy of Sciences.

Gi/o-Coupled Receptors Compete for Signaling to Adenylyl Cyclase in SH-SY5Y Cells and Reduce Opioid-Mediated cAMP Overshoot

J. Traynor, E. Levitt, L. Purington, 2011, Molecular Pharmacology.

Studies of μ-, κ-, and δ-Opioid Receptor Density and G Protein Activation in the Cortex and Thalamus of Monkeys

M. Ko, J. Woods, J. Traynor, 2003, Journal of Pharmacology and Experimental Therapeutics.

Mice Expressing Regulators of G protein Signaling–insensitive Gαo Define Roles of μ Opioid Receptor Gαo and Gαi Subunit Coupling in Inhibition of Presynaptic GABA Release

J. Traynor, Ming-hua Li, S. Ingram, 2021, Molecular Pharmacology.

Rapid Synthesis of Boc-2',6'-dimethyl-l-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics.

H. Mosberg, J. Traynor, Nicholas W. Griggs, 2015, ACS medicinal chemistry letters.

Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.

S. Husbands, J. Lewis, J. Woods, 2006, Journal of medicinal chemistry.

Cinnamoyl Derivatives of 7α‐Amino‐ and 7α‐(Aminomethyl)‐ N‐(cyclopropylmethyl)‐6,14‐endo‐ethanotetrahydronororipavines are High‐Potency Opioid Antagonists

S. Husbands, J. Lewis, J. Woods, 2000 .

Dynamic Coupling and Allosteric Networks in the Alpha Subunit of Heterotrimeric G Proteins

Xin-Qiu Yao, B. Grant, J. Traynor, 2016 .

Endogenous RGS proteins reduce mu-opioid receptor desensitization and down- regulation and adenylyl cyclase tolerance in C6 cells

J. Traynor, M. Clark, 2004 .

14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.

S. Husbands, J. Woods, J. Traynor, 2009, Journal of medicinal chemistry.

3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.

C. Neilan, S. Husbands, J. Woods, 2000, Journal of medicinal chemistry.

3-Alkyl ethers of clocinnamox : Delayed long-term μ-antagonists with variable μ efficacy

M. Aceto, L. Harris, S. Husbands, 1998 .

Nucleus accumbens shell excitability is decreased by methamphetamine self-administration and increased by 5-HT2C receptor inverse agonism and agonism

Steven M. Graves, J. Traynor, Xiu-Ti Hu, 2015, Neuropharmacology.

Characterisation of κ-opioid binding sites in rat and guinea-pig spinal cord

J. Traynor, F. D. Rodríguez, M. S. Wood, 1989, Neuropharmacology.

Author Correction: Structural insights into μ-opioid receptor activation

Kathryn E. Livingston, Evan N. Feinberg, R. Dror, 2020, Nature.

Opioid receptors in GtoPdb v.2023.1 Opioid receptors in GtoPdb v.2023.1

E. J. Simon, H. Ueda, M. Bruchas, 2023 .

Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor

Kathryn E. Livingston, J. Traynor, 2014, Proceedings of the National Academy of Sciences.

Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors

Kathryn E. Livingston, J. Traynor, M. Stanczyk, 2018, Molecular Pharmacology.

BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.

A. Coop, S. Husbands, J. Woods, 2000, The Journal of pharmacology and experimental therapeutics.

RGS9-2: probing an intracellular modulator of behavior as a drug target.

J. Traynor, B. Caldarone, V. Zachariou, 2009, Trends in pharmacological sciences.

Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.

R. Neubig, J. Traynor, H. Zhong, 2003, The Journal of biological chemistry.

Collision coupling, crosstalk, and compartmentalization in G-protein coupled receptor systems: can a single model explain disparate results?

Jennifer J Linderman, Christopher J Brinkerhoff, J. Linderman, 2008, Journal of theoretical biology.

Aspirin and human sleep.

J. Horne, J. Traynor, J. E. Percival, 1980, Electroencephalography and clinical neurophysiology.

Comparison of Peptidic and Nonpeptidic (cid:1) -Opioid Agonists on Guanosine 5 (cid:1) - O -(3-[ 35 S]thio)triphosphate ([ 35 S]GTP (cid:2) S) Binding in Brain Slices from Sprague-Dawley Rats

E. Jutkiewicz, K. Rice, J. Woods, 2005 .

Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.

E. Jutkiewicz, K. Rice, J. Woods, 2005, The Journal of pharmacology and experimental therapeutics.

Delta-opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats.

E. Jutkiewicz, K. Rice, J. Woods, 2004, The Journal of pharmacology and experimental therapeutics.

Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy

Alexander D. MacKerell, J. Traynor, Payal Chatterjee, 2023, Frontiers in Pharmacology.

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs

H. Carlson, J. Traynor, Wallace K. B. Chan, 2022, Scientific Reports.

Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists.

J. Traynor, M. Clark, A. Remmers, 2002, The Journal of pharmacology and experimental therapeutics.

Synthesis and cytotoxic activity of estrogen α-methylene-δ-lactones

P. Lockey, B. Marples, J. Traynor, 1984, Steroids.

Steroidal alpha-methylene delta-lactones as potential antitumor agents.

B. Marples, S. Dehal, J. Traynor, 1980, Journal of medicinal chemistry.

Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor

M. Aceto, L. Harris, A. Coop, 2014, Molecular pain.

Subtypes of the κ-opioid receptor: fact or fiction?

John R. Traynor, J. Traynor, 1989 .

Design of high affinity cyclic pentapeptide ligands for Κ-opioid receptors

I. Pogozheva, H. Mosberg, J. Traynor, 2005 .

Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence

E. Jutkiewicz, J. Traynor, J. Lamberts, 2017, Psychopharmacology.

Tolerance to μ‐opioid agonists in human neuroblastoma SH‐SY5Y cells as determined by changes in guanosine‐5′‐O‐(3‐[35S]‐thio)triphosphate binding

J. Traynor, J. Elliott, J. Traynor, 1997, British journal of pharmacology.

Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.

B. Roques, R. Maldonado, J. Traynor, 1999, European journal of pharmacology.

Behavioral effects of delta-opioid receptor agonists: potential antidepressants?

E. Jutkiewicz, K. Rice, J. Woods, 2002, Japanese journal of pharmacology.

70 Cloning and characterization of a δ opioid receptor from zebrafish

J. Traynor, A. Barrallo, R. Rodríguez, 1998 .

Cloning and characterization of a delta opioid receptor from zebrafish.

J. Traynor, A. Barrallo, R. Rodríguez, 1998, Biochemical Society transactions.

Opioid receptors in GtoPdb v.2021.3

E. J. Simon, H. Ueda, M. Bruchas, 2021, IUPHAR/BPS Guide to Pharmacology CITE.

Cytotoxic action of alpha‐methylene lactones towards HeLa cells in culture

P. Lockey, B. Marples, J. Traynor, 1989 .

Synthesis and Biological Evaluation of 14-Alkoxymorphinans. Part 10. 14-O-Methyl derivatives of 5-methylnaltrexone and 5-methylnaloxone†

J. Traynor, H. Schmidhammer, D. Patel, 1994 .

Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.

H. Mosberg, J. Traynor, Aaron M. Bender, 2014, Bioorganic & medicinal chemistry letters.

Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.

A. Coop, J. Traynor, Nicholas W. Griggs, 2017, Bioorganic & Medicinal Chemistry Letters.

Running Title : Evidence for a conserved opioid receptor allosteric site Corresponding

Kathryn E. Livingston, J. Traynor, M. Stanczyk, 2017 .

Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.

Kathryn E. Livingston, A. Christopoulos, M. Banks, 2015, Journal of medicinal chemistry.

Pharmacological Properties of d -Opioid Receptor – Mediated Behaviors: Agonist Efficacy and Receptor Reserve s

Kathryn E. Livingston, E. Jutkiewicz, K. Rice, 2020 .

In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor

S. Husbands, J. Traynor, M. Clark, 2013, Journal of psychopharmacology.

Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.

A. Coop, J. Traynor, Nicholas W. Griggs, 2017, Bioorganic & medicinal chemistry letters.

C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors

Vinod Kumar, S. Husbands, J. Lewis, 2015, Journal of medicinal chemistry.

Endogenous Regulator of G Protein Signaling Proteins Suppress G (cid:1) o-Dependent, (cid:2) -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization

R. Neubig, J. Traynor, M. Clark, 2004 .

Endogenous Regulator of G Protein Signaling Proteins Reduce μ-Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells

J. Traynor, M. Clark, 2005, Journal of Pharmacology and Experimental Therapeutics.

Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.

H. Mosberg, J. Traynor, Nicholas W. Griggs, 2019, Journal of Medicinal Chemistry.

Endogenous Regulators of G Protein Signaling Differentially Modulate Full and Partial μ-Opioid Agonists at Adenylyl Cyclase as Predicted by a Collision Coupling Model

J. Linderman, J. Traynor, M. Clark, 2008, Molecular Pharmacology.

Assays for G-protein-coupled receptor signaling using RGS-insensitive Galpha subunits.

J. Traynor, M. Clark, 2004, Methods in enzymology.

Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy

I. Pogozheva, H. Mosberg, J. Traynor, 2017, ACS chemical neuroscience.

Opus: University of Bath Online Publication Store

S. Husbands, J. Traynor, Mary J. Clark, 2022 .

Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the μ-Opioid Receptor

Marta Filizola, Paola Bisignano, Yi Shang, 2015, J. Chem. Inf. Model..

Opus: University of Bath Online Publication Store This Blockinis Blockinthe Blockinfinal Blockindraft Blockinpost-refereeing Blockinand Blockinis Allowed Blockinto Blockinbe Blockinmade Blockinavailable, Blockinwhere Blockinthe Blockinhost Institution Blockinmandates Blockinit, Blockinafter Blockin1

S. Husbands, J. Traynor, M. Clark, 2022 .

Isolation and Chemical Modification of Clerodane Diterpenoids from Salvia Species as Potential Agonists at the κ‐Opioid Receptor

S. Husbands, J. Traynor, M. Mahon, 2007, Chemistry & biodiversity.

Regulator of G protein–signaling proteins and addictive drugs

J. Traynor, 2010, Annals of the New York Academy of Sciences.

Antinociceptive and toxic effects of (+)‐epibatidine oxalate attributable to nicotinic agonist activity

J. Traynor, S. Fletcher, S. Freedman, 1994, British journal of pharmacology.